{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer%2C&page=12",
    "query": {
      "condition": "Cancer,",
      "page": 12
    },
    "page_size": 10
  },
  "pagination": {
    "page": 12,
    "page_size": 10,
    "total_count": 50439,
    "total_pages": 5044,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer%2C&page=13&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer%2C&page=11&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-13T16:09:05.245Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03238638",
      "title": "A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "epacadostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2018-09",
      "completion_date": "2020-12",
      "has_results": false,
      "last_update_posted_date": "2018-01-04",
      "last_synced_at": "2026-11-13T16:09:05.245Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03238638"
    },
    {
      "nct_id": "NCT02092038",
      "title": "Preoperative Chemoradiation for Glioblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "partial brain irradiation",
          "type": "RADIATION"
        },
        {
          "name": "stereotactic biopsy of brain tumor",
          "type": "PROCEDURE"
        },
        {
          "name": "craniotomy and tumor resection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "Tampa General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 1,
      "start_date": "2014-11",
      "completion_date": "2015-07",
      "has_results": false,
      "last_update_posted_date": "2015-11-10",
      "last_synced_at": "2026-11-13T16:09:05.245Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02092038"
    },
    {
      "nct_id": "NCT02518958",
      "title": "A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malignant Solid Tumor",
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "RRx-001",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EpicentRx, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2015-07-21",
      "completion_date": "2016-09-12",
      "has_results": false,
      "last_update_posted_date": "2019-11-18",
      "last_synced_at": "2026-11-13T16:09:05.245Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02518958"
    },
    {
      "nct_id": "NCT00445458",
      "title": "A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Breast Cancer",
        "Advanced Malignant Solid Tumors",
        "Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "HKI-272",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Puma Biotechnology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 110,
      "start_date": "2007-09-11",
      "completion_date": "2018-02-07",
      "has_results": true,
      "last_update_posted_date": "2018-07-26",
      "last_synced_at": "2026-11-13T16:09:05.245Z",
      "location_count": 8,
      "location_summary": "La Jolla, California • San Diego, California • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Lansing",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00445458"
    },
    {
      "nct_id": "NCT03847519",
      "title": "Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer, Non-Small Cell",
        "Metastatic Squamous Cell Carcinoma",
        "Metastatic Non-Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "ADXS-503",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Advaxis, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2019-02-12",
      "completion_date": "2022-02-22",
      "has_results": true,
      "last_update_posted_date": "2024-06-04",
      "last_synced_at": "2026-11-13T16:09:05.245Z",
      "location_count": 9,
      "location_summary": "Duarte, California • Los Angeles, California • Atlanta, Georgia + 6 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Westwood",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03847519"
    },
    {
      "nct_id": "NCT00165230",
      "title": "Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neuroendocrine Tumor"
      ],
      "interventions": [
        {
          "name": "Thalidomide",
          "type": "DRUG"
        },
        {
          "name": "Temodar",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2002-05",
      "completion_date": "2006-07",
      "has_results": false,
      "last_update_posted_date": "2009-04-28",
      "last_synced_at": "2026-11-13T16:09:05.245Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00165230"
    },
    {
      "nct_id": "NCT05581030",
      "title": "CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "Hyper CVAD Protocol (Standard of Care Multi-Agent Chemotherapy)",
          "type": "DRUG"
        },
        {
          "name": "Calaspargase Pegol",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 7,
      "start_date": "2023-05-01",
      "completion_date": "2026-10",
      "has_results": false,
      "last_update_posted_date": "2026-03-06",
      "last_synced_at": "2026-11-13T16:09:05.245Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05581030"
    },
    {
      "nct_id": "NCT04722692",
      "title": "Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "DCIS",
        "Breast Cancer",
        "Breast Neoplasms",
        "Sentinel Lymph Node"
      ],
      "interventions": [
        {
          "name": "Delayed SLND",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Late SLND",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Uppsala University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 500,
      "start_date": "2020-03-01",
      "completion_date": "2027-12-30",
      "has_results": false,
      "last_update_posted_date": "2023-08-03",
      "last_synced_at": "2026-11-13T16:09:05.245Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04722692"
    },
    {
      "nct_id": "NCT07174336",
      "title": "A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Neoplasms",
        "Neoplasm Metastasis"
      ],
      "interventions": [
        {
          "name": "LY4064809",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Ribociclib",
          "type": "DRUG"
        },
        {
          "name": "Palbociclib",
          "type": "DRUG"
        },
        {
          "name": "Abemaciclib",
          "type": "DRUG"
        },
        {
          "name": "Anastrozole",
          "type": "DRUG"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        },
        {
          "name": "Exemestane",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 800,
      "start_date": "2025-12-22",
      "completion_date": "2033-05",
      "has_results": false,
      "last_update_posted_date": "2026-11-04",
      "last_synced_at": "2026-11-13T16:09:05.245Z",
      "location_count": 132,
      "location_summary": "Anchorage, Alaska • Chandler, Arizona • Phoenix, Arizona + 112 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07174336"
    },
    {
      "nct_id": "NCT02504411",
      "title": "Outcomes of Disposable Distal Attachment Device (Endocuff and Transparent Plastic Cap) Assisted Colonoscopy",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Colorectal Neoplasms"
      ],
      "interventions": [
        {
          "name": "Device Assisted Colonoscopy",
          "type": "DEVICE"
        },
        {
          "name": "Standard Colonoscopy",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "The University of Texas Health Science Center, Houston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 0,
      "start_date": "2015-08",
      "completion_date": "2017-02-15",
      "has_results": false,
      "last_update_posted_date": "2018-08-13",
      "last_synced_at": "2026-11-13T16:09:05.245Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02504411"
    }
  ]
}